- A recently-announced phase III clinical trial for Long COVID will test a combination of the HIV drug Selzentry (Maraviroc) and the statin Lipitor (Atorvastatin). The FDA-approved trial is separate from the PolyBio trial of Maraviroc, and will test the two-drug combination for 32 weeks with 252 participants. The trial is being conducted by Healthbio Therapeutics, formerly IncellDx, based in Hayward, California, and Traverse City, Michigan. According to a press release, participants can pre-enroll for the trial at healthbioai.com.
- Researchers found that a part of the brain that produces cerebrospinal fluid was enlarged in people with Long COVID. In the study, published in Molecular Psychology, scientists found that the choroid plexus volume (ChP) was inflated from data of 129 people with the disease, compared to 36 controls. That enlarged ChP volume was associated with “cognitive performance, as well as structural and functional changes in the brain,” the authors concluded.
- A new review paper in the Journal of Translational Medicine assessed the search for blood-based biomarkers for myalgic encephalomyelitis (ME). “Different biochemical and electrophysiological properties which differentiate ME/CFS have been identified across studies,” the authors wrote, stating that the numerous findings and potential tests hold promise as potential biomarkers for the disease.
Follow Us
get the latest long covid news
Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
Trending
Recent ARTICLES
Tags
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance